IP Library Granted Patent US 8,497,112
Granted Patent B2
US 8,497,112 · App. 12/199,977 · Granted Jul 30, 2013

Method for producing viral vaccines

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,497,112
App. No.
12/199,977
Granted
Jul 30, 2013
Kind
B2
Abstract

The present invention provides a method for the manufacture of a preparation comprising virus antigens comprising a) inoculation of cells with infectious virus in a fluid, b) propagation of said virus in said cells, c) collecting said propagated virus, d) inactivating said collected virus, and e) treating said inactivated virus with a detergent, resulting in a preparation comprising viral antigens.

Claims (36)

1. A method for the manufacture of a preparation comprising virus antigens comprising

a) inoculating cells with infectious virus in a fluid,

b) propagating said virus in said cells,

c) collecting said virus propagated in said cells,

d) completely inactivating said virus collected from said cells,

e) purifying the inactivated virus, wherein the purification comprises ultracentrifugation or use of a sucrose gradient,

f) contacting the purified virus with a nuclease, and

g) treating said virus with detergent under conditions effective to yield a split virus,

resulting in a preparation comprising viral antigens, wherein the collected virus of step (c) is not purified prior to the inactivating step.

2. The method of claim 1 , wherein the step of collecting said propagated virus comprises separating the virus from said cells and/or cell debris of said cells after infection.

3. The method of claim 1 , wherein said inactivating is performed by addition of formaldehyde.

4. The method of claim 1 , wherein said inactivating is performed by UV irradiation.

5. The method of claim 1 , wherein said virus propagated in said cells is released into said fluid.

6. The method of claim 1 , wherein step (c) or (d) further comprises treating the virus with a nuclease.

7. The method of claim 6 , wherein said nuclease is Benzonase®.

8. The method of claim 1 , wherein said cells are in form of a cell culture during said virus propagation.

9. The method of claim 1 , wherein said cells are mammalian or avian cells.

10. The method of claim 1 , wherein said cells are epithelial cells.

11. The method of claim 8 , wherein said cells are Vero cells.

12. The method of claim 1 , wherein said virus is an enveloped virus.

13. The method of claim 12 , wherein said virus is an orthomyxo virus.

14. The method of claim 13 , wherein said virus is an influenza virus.

15. The method of claim 1 , wherein the concentration of non-viral protein during said inactivation is below 350 μg/ml.

16. The method of claim 1 , wherein said manufacture is on industrial scale amounts.

17. The method of claim 16 , wherein said inactivation is performed on at least 1 L virus containing fluid.

18. A method for the manufacture of a preparation comprising viral antigens comprising

a) obtaining a clarified supernatant comprising infectious virus,

b) inactivating said virus from step (a),

c) purifying the virus, wherein the purification comprises ultracentrifugation or use of a sucrose gradient,

d) contacting the inactivated, purified virus with a nuclease,

e) treating said virus with detergent under conditions effective to yield a split virus, and

f) further purifying said virus resulting in a preparation comprising viral antigens, wherein the clarified supernatant comprising the infectious virus is not purified prior to the inactivating step.

19. The method of claim 18 , wherein said clarified supernatant is obtained from a cell culture.

20. The method of claim 19 further comprising the step of stabilizing said viral antigens.

21. The method of claim 20 , wherein said viral antigens are stabilized by addition of an effective amount of Tween 80® (polysorbate 80).

22. The method of claim 21 , wherein Tween 80® is in an amount of about 0.125%.

Assignments (10)
CHANGE OF NAME Recorded Nov 20, 2025
From: RESILIENCE GOVERNMENT SERVICES, INC,
To: ALACHUA GOVERNMENT SERVICES, INC.
Reel/Frame 073279/0021 →
CHANGE OF NAME Recorded Sep 8, 2022
From: OLOGY BIOSERVICES, INC.
To: RESILIENCE GOVERNMENT SERVICES, INC.
Reel/Frame 061399/0903 →
RELEASE OF SECURITY INTEREST Recorded Aug 20, 2020
From: MIDCAP FINANCIAL TRUST, AS AGENT
To: OLOGY BIOSERVICES, INC.; NANO ADM, LLC
Reel/Frame 053561/0070 →
CHANGE OF NAME Recorded Jan 23, 2019
From: NANOTHERAPEUTICS, INC.
To: OLOGY BIOSERVICES, INC.
Reel/Frame 048117/0275 →
SECURITY INTEREST Recorded May 1, 2018
From: OLOGY BIOSERVICES, INC.
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 046050/0305 →
CORRECTIVE ASSIGNMENT TO CORRECT THE CORRESPONDENCE DATA PREVIOUSLY RECORDED ON REEL 037155 FRAME 0732. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded May 2, 2016
From: BAXALTA GMBH
To: NANOTHERAPEUTICS, INC.
Reel/Frame 038592/0044 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 24, 2015
From: BAXALTA GMBH
To: NANOTHERAPEUTICS, INC.
Reel/Frame 037155/0732 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 28, 2015
From: BAXTER INTERNATIONAL INC.
To: BAXALTA GMBH
Reel/Frame 036502/0752 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 18, 2015
From: BAXTER HEALTHCARE SA
To: BAXALTA GMBH
Reel/Frame 036388/0070 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 28, 2008
From: KISTNER, OTFRIED; TAUER, CHRISTA; BARRETT, NOEL; MUNDT, WOLFGANG
To: BAXTER INTERNATIONAL INC.; BAXTER HEALTHCARE S.A.
Reel/Frame 021747/0481 →